Caribou Biosciences Inc
NASDAQ:CRBU
Intrinsic Value
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. [ Read More ]
The intrinsic value of one CRBU stock under the Base Case scenario is 4.9 USD. Compared to the current market price of 3.76 USD, Caribou Biosciences Inc is Undervalued by 23%.
Valuation Backtest
Caribou Biosciences Inc
Run backtest to discover the historical profit from buying and selling CRBU stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Caribou Biosciences Inc
Current Assets | 338.8m |
Cash & Short-Term Investments | 328.8m |
Receivables | 3.9m |
Other Current Assets | 6.2m |
Non-Current Assets | 93.4m |
Long-Term Investments | 51.3m |
PP&E | 40.5m |
Other Non-Current Assets | 1.6m |
Current Liabilities | 28.3m |
Accounts Payable | 3.1m |
Accrued Liabilities | 20.9m |
Other Current Liabilities | 4.3m |
Non-Current Liabilities | 35.5m |
Other Non-Current Liabilities | 35.5m |
Earnings Waterfall
Caribou Biosciences Inc
Revenue
|
34.5m
USD
|
Operating Expenses
|
-150.5m
USD
|
Operating Income
|
-116.1m
USD
|
Other Expenses
|
14m
USD
|
Net Income
|
-102.1m
USD
|
Free Cash Flow Analysis
Caribou Biosciences Inc
CRBU Profitability Score
Profitability Due Diligence
Caribou Biosciences Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Caribou Biosciences Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
CRBU Solvency Score
Solvency Due Diligence
Caribou Biosciences Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Score
Caribou Biosciences Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CRBU Price Targets Summary
Caribou Biosciences Inc
According to Wall Street analysts, the average 1-year price target for CRBU is 20.4 USD with a low forecast of 10.1 USD and a high forecast of 31.5 USD.
Ownership
CRBU Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CRBU Price
Caribou Biosciences Inc
Average Annual Return | -31.49% |
Standard Deviation of Annual Returns | 35.86% |
Max Drawdown | -88% |
Market Capitalization | 332.6m USD |
Shares Outstanding | 90 314 496 |
Percentage of Shares Shorted | 11.84% |
CRBU News
Last Important Events
Caribou Biosciences Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Caribou Biosciences Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 97 full-time employees. The company went IPO on 2021-07-23. The firm is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients with devastating diseases. The Company’s CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), enables superior genome-editing precision to develop cell therapies that are specifically engineered for enhanced persistence. The company is advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (CAR)-T (CAR-T) and CAR-natural killer (CAR-NK) cell therapies for the treatment of patients with hematologic malignancies and solid tumors. Its lead product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 CAR-T cell therapy with programmed cell death protein 1 (PD-1) removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. The Company’s product candidate also includes CB-011, CB-012 and CB-012.
Contact
IPO
Employees
Officers
The intrinsic value of one CRBU stock under the Base Case scenario is 4.9 USD.
Compared to the current market price of 3.76 USD, Caribou Biosciences Inc is Undervalued by 23%.